MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum

Core Insights - MetaVia Inc. is set to showcase its innovative obesity and metabolic therapies at the Life Sciences Virtual Investor Forum on March 12, 2026, with CEO Hyung Heon Kim participating in a fireside chat [1] - The company is developing two key therapies: DA-1726 for obesity and vanoglipel for Metabolic Dysfunction-Associated Steatohepatitis (MASH) [1] Company Overview - MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases [1] - The company is advancing DA-1726, a novel oxyntomodulin analogue that acts as a dual agonist for GLP1R and GCGR, aiming for superior weight loss and glucose control [1] - Vanoglipel is a GPR119 agonist that enhances the release of gut peptides and has shown positive effects on liver health and glucose metabolism in pre-clinical studies [1] Clinical Development - DA-1726 has demonstrated best-in-class potential in a Phase 1 trial, showing significant weight loss, improved glucose control, and waist reduction [1] - Vanoglipel has exhibited direct hepatic action and glucose-lowering effects in a Phase 2a clinical study, addressing liver inflammation and metabolic dysfunction [1]